SHPMY (Shanghai Pharmaceuticals Holding Co) Notes Receivable: $0 Mil (As of Mar. 2026)


SHPMY Shanghai Pharmaceuticals Holding Co Ltd SHPMY
79 GF Score
Price $7.34
GF Value $9.36
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Notes Receivable?

Shanghai Pharmaceuticals Holding Co SHPMY -3.42% 79 Notes Receivable is $0 Mil as of Mar. 2026. GuruFocus rates SHPMY with a GF Score™ of 79/100 and a GF Value™ of $9.36 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Shanghai Pharmaceuticals Holding Co's Notes Receivable for the quarter that ended in Mar. 2026 was $0 Mil.

Shanghai Pharmaceuticals Holding Co Notes Receivable Related Terms

Shanghai Pharmaceuticals Holding Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Shanghai Pharmaceuticals Holding Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Pharmaceuticals Holding Co Notes Receivable Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shanghai Pharmaceuticals Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHPMY
79GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMY
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Pharmaceuticals Holding Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0 Mil mean?
Shanghai Pharmaceuticals Holding Co (SHPMY) has a Notes Receivable of $0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors.
Is Shanghai Pharmaceuticals Holding Co's Notes Receivable too high?
Shanghai Pharmaceuticals Holding Co's current Notes Receivable is $0 Mil. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Notes Receivable compare to MCK and CAH?
Shanghai Pharmaceuticals Holding Co's Notes Receivable of $0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Distribution company?
A good Notes Receivable depends on the Medical Distribution industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. Shanghai Pharmaceuticals Holding Co's current Notes Receivable is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (SHPMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.36, compared to a current price of $7.34 — trading 21.6% below its estimated fair value. The current Notes Receivable is $0 Mil. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMY), the current Notes Receivable is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Pharmaceuticals Holding Co (SHPMY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $7.34 is trading 21.6% below its estimated GF Value™ of $9.36. GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.

Key valuation signals for SHPMY:

  • Notes Receivable: $0 Mil
  • GF Value™: $9.36 vs. price of $7.34 (21.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the SHPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
79GF Score

Get the complete analysis for SHPMY

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.34
Price
$9.36
GF Value